Graphical Abstract Similar content being viewed by others Introduction Type 2 diabetes [1] is one of the major risk factors for stroke [2, 3] and a strong predictor of lasting post-stroke disability [4,5,6]
Activates GIP receptors to enhance fat metabolism, improve insulin sensitivity, and amplify the weight loss effects of GLP-1delivering results beyond single-pathway medications

Bronnen [1]Farmacotherapeutisch Kompas Tirzepatide preparaattekst Farmacotherapeutisch Kompas [2] [3] [4]Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) New England Journal of Medicine [5]Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine [6]Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 3-jaars data) New England Journal of Medicine [7]GVS-advies tirzepatide (Mounjaro) voor de behandeling van patinten met diabetes mellitus type 2 Zorginstituut Nederland [8]Farmacotherapeutisch Kompas Obesitas indicatietekst Farmacotherapeutisch Kompas [9] [10]Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) New England Journal of Medicine Blog over medisch afvallen Lees onze artikelen over medisch afvallen, leefstijl, voeding, medicatie, overgewicht, bewegen en gezond leven

These findings support biological delivery, but they do not establish that one form produces better clinical outcomes